EEDi-5285 TFA(2488952-40-3 Free base) is a potent and orally active small molecule inhibitor of embryonic ectodermal development (EED) with an IC50 value of 0.2 nM and excellent pharmacokinetics.
FTX-6058 is a potent orally active inhibitor targeting Embryonic Ectoderm Development (EED). It effectively induces HbF protein expression in both cell and murine models. This compound holds significant potential for researching select hemoglobinopathies such as sickle cell disease and β-thalassemia.
FTX-6058 hydrochloride is a potent and orally active inhibitor of Embryonic Ectoderm Development (EED), with the ability to induce HbF protein expression in both cell and murine models. This compound is particularly valuable in the research of select hemoglobinopathies, such as sickle cell disease and β-thalassemia.
EEDi-5273 is a highly potent and orally efficacious inhibitor of EED, with an approximate IC50 value of 0.2 nM. This compound exhibits exceptional activity, capable of achieving complete and persistent regression of tumors.
EED ligand 1 is a highly versatile, potent, and effective inhibitor that specifically targets the EED subunit of the polycomb repressive complex 2 (PRC2) methyltransferase.